Answers are grounded in this paper and cite their sources.
Accurate prediction of treatment response remains challenging in cancer. To facilitate response prediction in non-small cell lung cancer (NSCLC), we developed PRISM, an interpretable multiscale graph-learning framework for estimating treatment-specific objective response from pretreatment H&E whole-slide images. PRISM integrated multiresolution tissue representations with a cell-level tumor microenvironment (TME) hypergraph, thereby treating higher-order microenvironmental organization as a learnable component of treatment-response prediction. Samples from 7,082 patients from four Chinese centers were screened. PRISM was evaluated across treatment specific cohorts receiving targeted therapy (T), EGFR-targeted therapy (T_EGFR), immune checkpoint inhibitor–based therapy (ICI), chemoimmunotherapy (CI), and chemotherapy (C) using patient-level internal cross-validation, independent multicenter external validation, and prospective silent validation. PRISM predicted early objective responses across prespecified systemic therapies in NSCLC. In comparison to 18 established multiple-instance learning and computational pathology baseline models, PRISM remained competitive, with numerical advantages in selected tasks. Multiscale attribution and exploratory H&E-derived TME analyses provided spatial context for model predictions. Overall, PRISM offers a morphology-based framework for estimating early response to prespecified systemic therapies and warrants further prospective multicenter evaluation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: